SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Inclusion Criteria:

• Ability to understand and sign written informed consent.

• The diagnosis time of IPF before enrollment was less than 5 years.

• Combination of High Resolution Computerized Tomography (HRCT) pattern, and ifavailable surgical lung biopsy pattern, as assessed by central reviewers, areconsistent with diagnosis of IPF.

• Dlco (corrected for Hb): 30%-90% predicted of normal.

• FVC>= 50% predicted of normal.

Exclusion Criteria:

• Forced expiratory volume in one second (FEV1)/FVC ratio <0.7 after administration ofbronchodilator at Screening

• Expected to receive a lung transplant within 1 year from randomization or, forpatients at sites in the United States, on a lung transplant waiting list atrandomization.

• Known explanation for interstitial lung disease

• History of asthma or chronic obstructive pulmonary disease

• Active infection

• Ongoing IPF treatments including investigational therapy, immunosuppressants, andcytokine modulating agents

• History of unstable or deteriorating cardiac or pulmonary disease (other than IPF)within the previous 6 months